Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients

Oncologist - United States
doi 10.1634/theoncologist.2017-0452
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2016English

Advanced Non-Small Cell Lung Cancer in Elderly Patients

Breathe
PulmonaryRespiratory Medicine
2012English

Neutrophil-To-Lymphocyte Ratio as an Early Marker of Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Nivolumab

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2018English

Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

OncoImmunology
OncologyAllergyImmunology
2018English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Efficacy of Nivolumab in Pre-Treated Non-Small-Cell Lung Cancer Patients Harbouring KRAS Mutations

British Journal of Cancer
Cancer ResearchOncology
2018English

Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer

BMJ
1994English

Health State Utility Values in Advanced Non-Small Cell Lung Cancer Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy